A look at why some stockbrokers are successful, a study that brings oncologists' worst nightmare to life, and a timely Eureka moment in the war against parasites highlight this week's collection of Lab Notes. ...

WASHINGTON -- The FDA has approved the first drug for treatment of basal cell carcinoma, the most common type of skin cancer. ...

Newer biologic agents for treating moderate-to-severe plaque psoriasis can be considered for first-line use in some cases, according to new treatment guidelines from the National Psoriasis Foundation. ...

Tops in this week's edition, research in mice suggests that taking protein out of patients' diets a few days before surgery could reduce the risk of complications. ...

Most children and adolescents did not regularly use sunscreen despite reporting high rates of sunburn, data from a prospective cohort study showed. ...

The recently approved melanoma drug vemurafenib (Zelboraf) accelerates growth of nonmelanoma skin cancers but does not cause the secondary cancers, an international research team has concluded. ...

The overall death rate from melanoma has been declining among whites in recent years, but only among the most highly educated sector of the population, researchers found. ...

A novel small-molecule agent showed promise in early studies as a treatment for smallpox and other orthopoxvirus infections, researchers said. Also in this week's edition of Lab Notes, an ancient Chinese hangover remedy could hold the key to alcohol addiction. ...

The prognosis for cancer patients with brain metastases varies by the type of initial tumor, but the updated Graded Prognostic Assessment tool can help assess survival, researchers reported. ...

As part of the Year in Review series, ALLMedPage Today reporters are revisiting major news stories and following up with an analysis of the impact of the original report, as well as subsequent news generated by the initial publication. Here's what's transpired after publication of a news story about the...